Human Insulin Market Growth, Demand and Challenges of the Key Industry Players 2025-33
                     Global Human Insulin 
Market Research and 
Forecast Report 2025-
2033
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
Accord ing  to  t he  la t es t  repor t  by  I MARC Group,  t i t l ed  " Human  I nsu l i n  Market :  
G loba l  I ndust ry  T rends ,  Share ,  S ize ,  Grow th ,  Opportun i ty  and  Forecast  2025-
2033, "  t he  g loba l  human insu l in  m arke t  s i ze  reached USD 51 .3  B i l l i on  in  2024.
Human i nsu l in  (H I ) ,  a l so  known as  regu la r  insu l in ,  r e f e r s  t o  sho r t -ac t ing  insu l in  
Report syn thes ized  in  l abora t o r ies .  I t  m im ics  the  func t ion  o f  i nsu l i n  na tu ra l l y  p roduced 
by  t he  human  body  and i s  genera l l y  in j ec ted  subcu taneous ly  mu l t ip le  t imes  a  day .  
Highlight and I t  i s  b io -eng ineered  by  g rowing  insu l in  p ro t e ins  w i t h in  E -co l i  bac te r ia  (Escher i ch ia  co l i )  ce l l s .  
I t  i s  w ide ly  used  to  regu la t e  b lood  sugar  leve ls  in  pa t i en ts  w i t h  t ype  I  and  I I  
Description d iabet es  and  p romote  g lucose  up take  f rom the  b lood  in to  i n t e rna l  o rgans  and  
t i s sues ,  such  as  l i ve r  and  f a t  ce l l s .  I t  a l so  i nh ib i t s  hepa t i c  g lucose  p roduc t ion  and  
enhances  the  p ro te in  syn t hes i s  o f  t he  body .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/human- insu l in -marke t / r eques tsam ple
Report Description
G l o b a l  H u m a n  I n s u l i n  M a r k e t  T r e n d s :
T h e  s u r g i n g  i n c i d e n c e s  o f  d i a b e t e s  d u e  t o  t h e  a g i n g  p o p u l a t i o n ,  s e d e n t a r y  l i f e s t y l e s ,  a n d  u n h e a l t h y  d i e t a r y  h a b i t s  r e p r e s e n t  t h e  
p r i m a r y  f a c t o r  d r i v i n g  t h e  m a r k e t  g r o w t h .  A d d i t i o n a l l y ,  t h e r e  h a s  b e e n  g r o w i n g  c o n s u m e r  a w a r e n e s s  r e g a r d i n g  t h e  c o m p l i c a t i o n s  o f  
p r o l o n g e d  d i a b e t e s ,  s u c h  a s  c a t a r a c t s ,  h e a r t  a t t a c k s ,  a n d  k i d n e y  f a i l u r e .  I n  l i n e  w i t h  t h i s ,  t h e  e s c a l a t i n g  d e m a n d  f o r  b i o s i m i l a r  d r u g s  
o n  a c c o u n t  o f  t h e i r  h i g h  e f f i c i e n c y  a n d  c o s t - e f f e c t i v e n e s s  h a s  c a t a l y z e d  m a r k e t  g r o w t h .  F u r t h e r m o r e ,  s e v e r a l  k e y  p l a y e r s  a r e  
e x t e n s i v e l y  i n v e s t i n g  i n  r e s e a r c h  a n d  d e v e l o p m e n t  ( R & D )  a c t i v i t i e s  t o  d e v e l o p  o r a l  i n s u l i n  v a r i a n t s  t h a t  p r o v i d e  a  s a f e ,  e f f e c t i v e ,  a n d  
c o n v e n i e n t  m e t h o d  o f  d e l i v e r i n g  i n s u l i n  t h e r a p y .  A p a r t  f r o m  t h i s ,  t h e  i n t r o d u c t i o n  o f  p e n  d e v i c e s  a n d  s a f e t y  p e n  n e e d l e s  t h a t  c a u s e  
m i n i m a l  d i s c o m f o r t  a n d  r e d u c e  t h e  r i s k s  o f  i n j u r i e s ,  i n f e c t i o n s ,  a n d  b l o o d b o r n e  p a t h o g e n  t r a n s m i s s i o n  h a s  a c c e l e r a t e d  t h e  p r o d u c t  
a d o p t i o n  r a t e .  M o r e o v e r ,  t h e  i m p l e m e n t a t i o n  o f  s t r i n g e n t  g o v e r n m e n t  p o l i c i e s  a g a i n s t  n e e d l e  s t i c k  i n j u r i e s  a n d  t h e  s h i f t i n g  c o n s u m e r  
p r e f e r e n c e s  t o w a r d  m i n i m a l l y  i n v a s i v e  ( M I )  d e v i c e s  h a v e  e n c o u r a g e d  t h e  u s a g e  o f  p e n  d e v i c e s  a n d  s a f e t y  p e n  n e e d l e s  f o r  H I  
a d m i n i s t r a t i o n .  O t h e r  f a c t o r s ,  i n c l u d i n g  t h e  e x p a n d i n g  o b e s e  p o p u l a t i o n ,  i m p r o v i n g  h e a l t h c a r e  i n f r a s t r u c t u r e ,  i n c r e a s i n g  c o n s u m e r  
h e a l t h  c o n s c i o u s n e s s ,  r e c e n t  a d v a n c e m e n t s  i n  t h e  b i o t e c h n o l o g y  f i e l d ,  a n d  p r o d u c t  i n n o v a t i o n s ,  a r e  a l s o  p r o v i d i n g  a  p o s i t i v e  t h r u s t  t o  
t h e  m a r k e t  g r o w t h .
L o o k i n g  f o r w a r d ,  t h e  m a r k e t  v a l u e  i s  e x p e c t e d  t o  r e a c h  U S D  8 5 . 1  B i l l i o n  b y  2 0 3 3 ,  e x h i b i t i n g  a  C A G R  o f  5 . 7 %  d u r i n g  t h e  f o r e c a s t  
p e r i o d  ( 2 0 2 5 - 2 0 3 3 ) .
V i e w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w w w . i m a r c g r o u p . c o m / h u m a n - i n s u l i n - m a r k e t
Breakup by Product Type:
•   Drugs
o Human Insul in Analogs and Biosimi lars
 Rapid Acting
 Long Acting
 Premixed
Report o Human Insul in Biologics
 Short Act ing
Segmentation
 Intermediate Acting
 Premixed
•   Del ivery Devices
o Pens
 Reusable Pens
 Disposable Pens
o Pen Needles
 Standard Pen Needles
 Safety Pen Needles
o Syringes
o Others
Breakup by Distribution Channel:
Report • Retai l  Pharmacies
Segmentation • Hospital  Pharmacies
• Online Retai l  Stores
• Others
Breakup by Disease Type:
• Type I  Diabetes
• Type I I  Diabetes
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
Report 
Segmentation
• B. Braun Melsungen AG
• Becton, Dickinson and Company (BD)
• Biocon
Competitive • El i  Li l ly and Company
Landscape • Gulf Pharmaceutical Industr ies ( Julphar)
• Novo Nordisk A/S
with Key • Pfi zer Inc.
Players • Groupe Sanofi
• SEDICO Co.
• Wockhardt Limited
• Ypsomed AG
What was the size of the global human insulin market in 
2024?
What is the expected growth rate of the global human 
insulin market during 2025-2033?
What are the key factors driving the global human 
insulin market?
Key 
What has been the impact of COVID-19 on the global 
human insulin market?
Questions 
What is the breakup of the global human insulin market 
Answered in based on the product type?
the Report What is the breakup of the global human insulin market 
based on the distribution channel?
What is the breakup of the global human insulin market 
based on the disease type?
What are the key regions in the global human insulin 
market?
Who are the key players/companies in the global human 
insulin market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  H u m a n  I n s u l i n  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  P r o d u c t  T y p e
    6 . 1     D r u g s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  B r e a k u p  b y  T y p e
           6 . 1 . 2 . 1  H u m a n  I n s u l i n  A n a l o g s  a n d  B i o s i m i l a r s
              6 . 1 . 2 . 1 . 1  R a p i d  A c t i n g
                 6 . 1 . 2 . 1 . 1 . 1  M a r k e t  T r e n d s
                 6 . 1 . 2 . 1 . 1 . 2  M a r k e t  F o r e c a s t
              6 . 1 . 2 . 1 . 2  L o n g  A c t i n g
                 6 . 1 . 2 . 1 . 2 . 1  M a r k e t  T r e n d s
                 6 . 1 . 2 . 1 . 2 . 2  M a r k e t  F o r e c a s t
       
              6 . 1 . 2 . 1 . 3  P r e m i x e d
                 6 . 1 . 2 . 1 . 3 . 1  M a r k e t  T r e n d s
                 6 . 1 . 2 . 1 . 3 . 2  M a r k e t  F o r e c a s t
           6 . 1 . 2 . 2  H u m a n  I n s u l i n  B i o l o g i c s
              6 . 1 . 2 . 2 . 1  S h o r t  A c t i n g
                 6 . 1 . 2 . 2 . 1 . 1  M a r k e t  T r e n d s
                 6 . 1 . 2 . 2 . 1 . 2  M a r k e t  F o r e c a s t
              6 . 1 . 2 . 2 . 2  I n t e r m e d i a t e  A c t i n g
                 6 . 1 . 2 . 2 . 2 . 1  M a r k e t  T r e n d s
                 6 . 1 . 2 . 2 . 2 . 2  M a r k e t  F o r e c a s t
              6 . 1 . 2 . 2 . 3  P r e m i x e d
                 6 . 1 . 2 . 2 . 3 . 1  M a r k e t  T r e n d s
Table of                  6 . 1 . 2 . 2 . 3 . 2  M a r k e t  F o r e c a s t        6 . 1 . 3  M a r k e t  F o r e c a s t
     6 . 2     D e l i v e r y  D e v i c e s
        6 . 2 . 1  M a r k e t  T r e n d s
Contents         6 . 2 . 2  M a r k e t  B r e a k u p  b y  T y p e
           6 . 2 . 2 . 1  P e n s
               6 . 2 . 2 . 1 . 1  R e u s a b l e  P e n s
               6 . 2 . 2 . 1 . 2  D i s p o s a b l e  P e n s
           6 . 2 . 2 . 2  P e n  N e e d l e s
               6 . 2 . 2 . 2 . 1  S t a n d a r d  P e n  N e e d l e s
               6 . 2 . 2 . 2 . 2  S a f e t y  P e n  N e e d l e s
           6 . 2 . 2 . 3  S y r i n g e s
           6 . 2 . 2 . 4  O t h e r s
        6 . 2 . 3  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D i s t r i b u t i o n  C h a n n e l
    7 . 1     R e t a i l  P h a r m a c i e s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /h um a n- i n su l i n -m arke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: